Human Recombinant Monoclonal SPIKE antibody. Carrier free. Suitable for I-ELISA and reacts with Recombinant full length protein - SARS-CoV-2 samples. Cited in 2 publications.
IgG1
Human
Constituents: 100% PBS
Liquid
Monoclonal
I-ELISA | |
---|---|
Recombinant full length protein - SARS-CoV-2 | Tested |
SARS-CoV-2 | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant full length protein - SARS-CoV-2 | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species SARS-CoV-2 | Dilution info - | Notes - |
Spike protein S1Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2 (PubMed:32142651, PubMed:33607086, PubMed:32155444). When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane (PubMed:34561887). When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis leading to fusion of the virion membrane with the host endosomal membrane (PubMed:32221306, PubMed:32075877). Alternatively, may use NRP1/NRP2 (PubMed:33082294, PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The use of NRP1/NRP2 receptors may explain the tropism of the virus in human olfactory epithelial cells, which express these molecules at high levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S contains three hinges, giving the head unexpected orientational freedom (PubMed:32817270).Spike protein S2Precursor of the fusion protein processed in the biosynthesis of the S protein and the formation of virus particle. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains two viral fusion peptides that are unmasked after cleavage. The S2/S2' cleavage occurs during virus entry at the cell membrane by host TMPRSS2 (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616). In either case, this triggers an extensive and irreversible conformational change leading to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.Spike protein S2'Subunit of the fusion protein that is processed upon entry into the host cell. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains a viral fusion peptide that is unmasked after S2 cleavage. This cleavage can occur at the cell membrane by host TMPRSS2 or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616). In either case, this triggers an extensive and irreversible conformational change that leads to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, 2, S
Human Recombinant Monoclonal SPIKE antibody. Carrier free. Suitable for I-ELISA and reacts with Recombinant full length protein - SARS-CoV-2 samples. Cited in 2 publications.
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, 2, S
IgG1
Human
Constituents: 100% PBS
Liquid
Monoclonal
Yes
CV30
Reported Affinity to SARS-CoV-2 RBD: 3.6 nM
Reported Neutralisation: Achieves 100% neutralisation by blocking Spike-ACE2 interaction through an interaction that is slightly higher affinity
Reported binding epitope: (from crystal structure of CV30 bound to RBD) – 29 residues in the concave ACE2-binding epitope (also known as the receptor-binding motif (RBM)) of the SARS-CoV-2 RBD
No cross-reactivity to SARS-CoV-1 Spike protein due to low conservation of interacting residues.
kappa
Blue Ice
+4°C
Do Not Freeze
CV30 cross-reacts with both SARS-CoV-2 Spike RBD and Ectodomain. CV30 demonstrates significant neutralising ability in in-direct ELISA, measuring competitive binding of CV30 to SARS-CoV-2 Spike RBD in the presence of human ACE2.
ab277515 is the carrier-free version of Anti-SARS-CoV-2 Spike RBD antibody [CV30] ab277513.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This supplementary information is collated from multiple sources and compiled automatically.
The SARS-CoV-2 Spike RBD also known commonly as the Receptor Binding Domain of the spike protein plays an important role in viral entry into host cells. This domain has a mass of approximately 21 kDa. It is located on the surface of the virus and facilitates binding to the host cell receptor primarily ACE2 which permits viral entry and replication. The Spike RBD is also a target for neutralizing antibodies which are essential in immune response against the virus. The domain displays various mutations particularly in variants of concern such as Omicron which can affect binding efficiency and immune evasion.
The SARS-CoV-2 Spike RBD interacts directly with the host ACE2 receptor to mediate entry of the virus into host cells. This interaction is necessary for the virus to fuse with the host cell membrane which allows viral RNA to enter the host cell and begin replication. The Spike protein of which the RBD is a part forms a trimeric complex on the virus surface that is important for host interaction. Variations in the Spike RBD such as mutations like Arg319-Phe541 have significant impacts on the binding affinity to ACE2 and the effectiveness of vaccine-elicited antibodies.
The Spike RBD of SARS-CoV-2 is vital in the entry pathway of the virus into the host cell. It is prominently involved in the ACE2-mediated signaling pathway with ACE2 playing the key role as the cellular receptor. This pathway is integral to the pathogenesis of COVID-19. Additionally the presence of the virus in host cells can trigger inflammatory pathways via infection-induced signaling cascades which can lead to exacerbated immune responses.
The SARS-CoV-2 Spike RBD is inherently linked to COVID-19 pathogenesis. Variants such as Omicron have alterations within the RBD that may confer increased transmissibility and resistance to neutralizing antibodies. These mutations can influence disease severity and vaccine effectiveness. The interaction between the Spike RBD and ACE2 receptor underlies the symptomatic manifestations of COVID-19 including respiratory distress and systemic inflammation. The emergence of RBD-targeted therapeutics and vaccines addresses its critical role in infection aiming to block the binding and prevent disease progression.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was produced using the same clone but in a different formulation, Anti-SARS-CoV-2 Spike RBD antibody [CV30] ab277513.
Indirect ELISA showing Anti-SARS-CoV-2 Spike RBD antibody [CV30] ab277513 (CV30) binding to purified His-tagged SARS-CoV2-RBD. Plates were coated with 100ng/well purified protein and binding of Anti-SARS-CoV-2 Spike RBD antibody [CV30] ab277513 assessed in serial dilution from 100ng/ml primary antibody in duplicate. Binding was detected using Goat Anti-Human IgG Fc (HRP) preadsorbed ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
This data was produced using the same clone but in a different formulation, Anti-SARS-CoV-2 Spike RBD antibody [CV30] ab277513.
Indirect ELISA showing Anti-SARS-CoV-2 Spike RBD antibody [CV30] ab277513 (CV30) binding to Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)). Plates were coated with 100ng/well Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105 and binding of Anti-SARS-CoV-2 Spike RBD antibody [CV30] ab277513 assessed in serial dilution from 100ng/ml primary antibody in duplicate. Binding was detected using Goat Anti-Human IgG Fc (HRP) preadsorbed ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
This data was produced using the same clone but in a different formulation, Anti-SARS-CoV-2 Spike RBD antibody [CV30] ab277513.
Indirect competition ELISA showing competitive binding of Anti-SARS-CoV-2 Spike RBD antibody [CV30] ab277513 (CV30) to purified Fc-tagged SARS-CoV2-RBD in the presence of 2nM His-tagged human ACE2. Plates were coated with 100ng/well SARS-CoV2-RBD and binding of the recombinant ACE2 determined in duplicate in the presence of a serial dilution (from 330nM) of primary antibody. His-tagged ACE2 binding was detected using HRP Anti-6X His tag® antibody ab1187, an anti-His tag secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
This data was produced using the same clone but in a different formulation, Anti-SARS-CoV-2 Spike RBD antibody [CV30] ab277513.
Indirect competition ELISA showing competitive binding of Anti-SARS-CoV-2 Spike RBD antibody [CV30] ab277513 (CV30) to Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)) in the presence of 2nM His-tagged human ACE2. Plates were coated with 100ng/well Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105 and binding of the recombinant ACE2 determined in duplicate in the presence of a serial dilution (from 330nM) of primary antibody. His-tagged ACE2 binding was detected using HRP Anti-6X His tag® antibody ab1187, an anti-His tag secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com